Cell Therapeutics Reports Third Quarter 2013 Financial Results

Published November 3, 2013

Cell Therapeutics Reports Third Quarter 2013 Financial Results
Reached agreement with the U.S. Food and Drug Administration (FDA) on a SPA for the planned pivotal Phase 3 clinical trial, known as PERSIST-2, evaluating pacritinib compared to best available therapy, including approved JAK2 inhibitors such as …
Read more on Sacramento Bee

Remarks by President Obama and Governor Deval Patrick on the Affordable …
And, frankly, if every governor was working as hard as Deval, or Governor O'Malley in Maryland, or Governor Cuomo in New York, to make this law work for their citizens, as opposed to thinking politically, about 8 in 10 Americans would be getting health …
Read more on eNews Park Forest

ASICS America Revs Up Battle Against Cancer With Prostate Cancer Awareness …
For the last 20 years, the Prostate Cancer Foundation has worked tirelessly to find unique strategies for identifying and investing in the most promising research programs, generating life-saving results. The organization channels resources to the …
Read more on Sacramento Bee

Array BioPharma Reports Financial Results For The First Quarter Of Fiscal 2014 …
The cost of partnered programs increased to $ 10.7 million, compared to $ 6.5 million for the same period last year, largely due to increased co-development costs with Novartis related to the start of three MEK162 Phase 3 studies. Research and …
Read more on Sacramento Bee